Amgen Beats and Raises, but Can New Growth Drugs Outrun Crumbling Legacy Sales Fast Enough to Justify a 60% Rally?

Shares surged 3.9% to $479.04 Wednesday morning — punching through the 52-week high — after Amgen posted a third-quarter earnings beat that reversed an initial after-hours dip. The swing tells a story of a market still deciding whether the biotech giant's growth engines are powerful enough to offset mounting patent-cliff losses.

A Big Beat That Almost Didn't Matter. Amgen reported adjusted earnings of $6.45 per share on revenue of $10.37 billion, topping the $5.79 EPS consensus and $10.07 billion revenue estimate.

The company raised full-year 2026 guidance to $38.9–$39.7 billion in revenue and $22.90–$23.70 in adjusted EPS. Yet the prior guidance ranges were $38.2–$39.4 billion and $22.30–$23.50, putting the new midpoints only about 1% above Wall Street models — barely enough to excite shareholders sitting on a stock that had already gained 45% year-to-date . The initial after-hours selloff reflected a classic "beat and retreat" — strong headlines that merely met rather than exceeded the optimism already baked into the price.

Heart and Bone Drugs Are Carrying the Company. Repatha, a cholesterol-lowering injection, delivered record quarterly sales of $1.085 billion, up 37% year over year.

Evenity, an osteoporosis treatment, grew 39% to $751 million, and Tezspire, a severe-asthma drug, jumped 43% to $538 million.

Together, Amgen's six key growth products surged 27% and now represent over 70% of product sales — a radical reshaping of the revenue mix that gives management breathing room.

The Patent Cliff Is Real and Accelerating. Prolia, the bone-loss drug, saw sales collapse 45% to $632 million, while cancer-drug Xgeva plunged 47% to $288 million as generic-like competitors flooded the market. Those two products together generated roughly $1.8 billion a year ago , meaning Amgen must keep finding close to a billion dollars annually in new sales just to stand still.

The Weight-Loss Wildcard Looms Over Everything. Amgen's entire near-term obesity bet rests on MariTide, a drug designed to require only four to six injections per year — far less frequent than current blockbusters from Eli Lilly and Novo Nordisk. Initial Phase 3 results are expected in 2027.

Meanwhile, R&D spending climbed 11% this quarter , and operating margins held at 47% . If MariTide data disappoint, a stock trading near $479 — at roughly 21× forward earnings — has limited margin for error.